Worldwide Recent Trend “Erectile Dysfunction Drugs Market” Research Report Available to MarketResearchFuture.com the Market of Erectile Dysfunction Drugs is driven by the Number of Drugs Available in the Market and Increasing Number of Men Suffering from this Disorder Available.
Erectile Dysfunction Drugs Market – Key Players
Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S), Vivus, Inc. (U.S), and others are some of the prominent players at the forefront of competition in the global erectile dysfunction drugs market and are profiled in MRFR Analysis.
Sample Report @ https://www.marketresearchfuture.com/sample_request/1313
Global Erectile Dysfunction Drugs Market – Scenario
Inability to keep firm erection firm enough during sexual intercourse in known as erectile dysfunction. It is also known as impotence. It is a common medical disorder primarily affecting men older than 40 years of age. Stress and mental health concerns may worsen the problem of erectile dysfunction. Physical and psychological issues may also cause erectile dysfunction.
There is also an increase in the competition among the major market players. Patent expiry of number of blockbuster drugs, availability of counterfeit drugs and increasing manufactures of generic drugs in the market may result in the decline of erectile dysfunction drugs market.
Global market of erectile dysfunction drugs is expected to reach USD 2.95 billion in 2027 from USD 1.65 billion in 2022 with a CAGR of approximately 6.5% during the forecast period 2022-2027.
Global Erectile Dysfunction Drugs Market – Segmentation
Global Erectile Dysfunction Drugs Market has been segmented on the basis of product which includes Viagra, Cialis, Levitra, Stendra, Zydena and other drugs and on the basis of end users the market is segmented into Hospitals, clinics, pharmaceutical companies and others.
Global Erectile Dysfunction Drugs Market – Regional Analysis
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.
Europe holds the major share of the market, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.
More Details with Brief TOC @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313
Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.